Jorge Cortes

Augusta University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (8)

Elisabetta Abruzzese

UNIVERSITY TOR VERGATA

ITALY

View details

Avirup Guha

Augusta University

UNITED STATES

View details

Ghayas C. Issa

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Daniel DeAngelo

Chief of the Division of Leukemia

Dana-Farber Cancer Institute

UNITED STATES

View details

Meng-Han Tsai

Augusta University

UNITED STATES

View details

Malcolm Bevel

Assistant Professor

Augusta University Medical College of Georgia

UNITED STATES

View details

elyce cardonick

Professor

Cooper Medical School of Rowan University

UNITED STATES

View details

vamsi kota

Augusta University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jorge Cortes

Research Interests

Explore related searches

Contact this professor

Articles (30)

Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia

Age-related disparities in survival following colorectal cancer diagnosis in an underserved community in Georgia

Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL

Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm

Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome

Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?

Welcome to Blood Global Hematology

Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results

Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding

Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Global Trial Representation and Availability of Tyrosine Kinase Inhibitors for Treatment of Chronic Myeloid Leukemia

Cardiovascular Diseases Increase Cancer Mortality in Adults: NHANES‐Continuous Study

The Intersection of Melanoma Survival and Social Determinants of Health in the United States: A Systematic Review

Bringing global hematology research to the forefront

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors

Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Representation of the population in need for pivotal clinical trials in lymphomas

Disparities in Survival of Hematologic Malignancies in the Context of Social Determinants of Health: A Systematic Review

Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia

Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia

Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML

Collaborators (8)

Elisabetta Abruzzese

Avirup Guha

Ghayas C. Issa

Daniel DeAngelo

Meng-Han Tsai

Malcolm Bevel

elyce cardonick

vamsi kota

Make your next move.